34
Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Embed Size (px)

Citation preview

Page 1: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Screening for Colorectal Cancer

Cancer Symposium: Measuring the Benefits of Screening and

Treatment

October 2007

Page 2: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Why should we screen of colon and rectal cancer?

Page 3: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Because it is common

• Third most common cancer in Canada– 20,400 new cases

• Second most lethal– 8,700 deaths

• The most lethal among non smokers

Page 4: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Natural History

• The polyp cancer sequence

• Surgical and endoscopic techniques

Page 5: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Because we can

Page 6: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Screening for CRC

• No symptoms

• Average risk

• High risk

Page 7: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Screening for CRC

• Average risk individual– When to start?

• Age 50– Incidence 1:500 age 40 -49 y– 1:125 50-59 y– 1:50 60-69 y

Page 8: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Fecal Occult Blood Testing

• The only screening test with Level I evidence that it can decrease the mortality from CRC– NEJM 1993 Minnesota Trial– Lancet 1996 European Study

• 18 yr follow-up from the Minnesota Trial shows an 21% mortality reduction in the screening cohort

Page 9: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

FOBT

• “2 samples from each of 3 consecutive stool samples, with dietary restrictions if using a guaiac based test”

• Any positive result followed up with colonoscopy

Page 10: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

FOBT

• How often?

• High false positive rate

• Significant false negative rate

Page 11: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Canadian Task Force on Preventative Health

• “the number needed to screen for 10 years to avert one death from colorectal cancer is 1173”

Page 12: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Flexible Sigmoidoscopy: The Good

• The scope is 50 cm long– Easier– Perforation rate is low

• Most cancers (in average risk individuals) are within 50 cm

• Biopsy and polypectomy is possible

Page 13: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Flexible Sigmoidoscopy: The Bad

• The scope is 50 cm long

• Perforation rate is 1.4 per 1000

• Prep is necessary

Page 14: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Flexible Sigmoidoscopy

• Good for 5 years

• ? Should one do a full colonoscopy if a low risk polyp is found in the distal colon– Lancet 2002 UK RCT found an 80%

mortality reduction form CRC

Page 15: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Double Contrast Barium Enema

• No randomized trails that evaluate this as a screening tool for average risk individuals

• It does not see the rectum well

• It misses 50% of polyps < 1.0 cm

• Q 5 years

Page 16: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Combinations

• DCBE and Flex sig– No data

• FOBT and Flex sig– Limited data

Page 17: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Colonoscopy: The Good

• Although there is no evidence……

• Allows diagnostic biopsy and endoscopic removal of polyps

• Shelf life of 10 years in average risk individuals

Page 18: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Colonoscopy: The Bad

• Highly trained personnel

• Resource intense

• Expensive

• Do we have the capacity?

Page 19: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Colonoscopy: The Ugly

• Prep

• Perforation risk– 1:1000 all comers– 1:2000 screening– 1:15000 mortality

Page 20: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Emerging Technologies

• Fecal DNA analysis

• Virtual colonoscopy

Page 21: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Virtual Colonoscopy

Page 22: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Emerging Technologies

• Fecal DNA analysis

• Virtual colonoscopy

• Micro array gene expression analysis

Page 23: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

High Risk Individuals

• Good news and bad news

• Family History

• FAP

• HNPCC

• IBD

Page 24: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Family history

• 1 first degree relative < 60 with CRC or polyp disease or

• 2 first degree relatives with CRC at any age

• Begin at age 40, or 10 years younger than the youngest relative and continue q 5 years

Page 25: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Family history

• 1 First degree relative > 60 with CRC or polyp disease or

• 2 second degree relatives with CRC at any age

• Should be screened as an average risk but beginning at age 40

Page 26: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Family History

• 1 second degree relative or any number of third degree relatives should be screened as average risk

Page 27: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Familial Adenomatous Polyposis (FAP)

• Flexible sigmoidoscopy at age 14

• +/- genetic testing

Page 28: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Hereditary Non-polyposis Colon Cancer (HNPCC)

• Amsterdam II Criteria– 3 relatives (at least I first degree)– Successive generations– One with Ca <50– FAP r/o

Page 29: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

HNPCC

• Colonoscopy q 2 years

• +/- genetic testing for MMR gene mutation

• +/- genomic analysis of tissue for micro satellite instability

Page 30: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Patients with Inflammatory Bowel Disease

• Same for UC or Crohns

• 8 years after the onset of disease in pancolitis• 15 years after onset in Left sided disease

• Colonoscopy q 1 - 2 years

Page 31: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Patients with a history of Polyps

• Advanced adenoma– >10 mm– Villous architecture– HGD

• >2 polyps less than 10 mm

• AGA……3 years• CAG…….clinical judgment

Page 32: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Patients with a history of polyps

• One or two polyps , each less than or = 10 mm

• 5 years

Page 33: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Summary

• Screening is good• Begin at age 50 in average risk individuals• Options

– FOBT +/- colonoscopy– colonoscopy

• High risk individuals should have colonoscopy

Page 34: Screening for Colorectal Cancer Cancer Symposium: Measuring the Benefits of Screening and Treatment October 2007

Questions